Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
AR(Androgen Receptor) | 1 |
Target |
Mechanism AR antagonists |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. FR |
First Approval Date01 Jan 1987 |
Target |
Mechanism H2 receptor antagonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Apr 2024 |
Sponsor / Collaborator University of Lleida [+1] |
Start Date12 Dec 2023 |
Sponsor / Collaborator |
Start Date24 Nov 2022 |
Sponsor / Collaborator Groupe Lactalis SA [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Nilutamide ( AR ) | Prostatic Cancer More | Approved |
Baxitozine ( H2 receptor ) | Stomach Ulcer More | Discontinued |